Form 4: Orchestra BioMed Holdings Director Awarded RSUs and Options

Orchestra BioMed Holdings, Inc. reports that Director Pamela Ann Connealy was granted restricted stock units and stock options on June 23, 2026.

Summary

• Director Pamela Ann Connealy received an award of 17,327 Restricted Stock Units (RSUs) on June 23, 2026.
• These RSUs represent a contingent right to receive one share of Common Stock per unit.
• The RSUs are set to vest one year after the grant date, contingent on continued service.
• Additionally, Connealy was granted 21,277 stock options on June 23, 2026, with an exercise price of $4.04.
• These stock options will also vest one year after the grant date, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard compensation for a director and does not inherently signal positive or negative performance.

Positives

• Director compensation through equity awards (RSUs and options) indicates management's commitment to aligning executive interests with shareholder value.
• The grant of stock options with an exercise price of $4.04 suggests a belief in future stock price appreciation above this level.
• The vesting schedule tied to continued service incentivizes long-term commitment from the director.

Risks

• The value of the RSUs and stock options is subject to the future performance of Orchestra BioMed Holdings' stock price.
• Vesting is contingent on continued service, meaning the awards could be forfeited if the director leaves the company before the vesting date.

Future Outlook

The vesting of RSUs and stock options is tied to continued service, with specific vesting dates in the future. The stock options have an expiration date in 2036.

Industry Context

StockSavvy.ai notes that the issuance of RSUs and stock options to directors is a common practice in the biotechnology and healthcare sectors to attract and retain talent and align incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The issuance of equity awards to directors is a standard practice that aligns director incentives with shareholder interests, potentially leading to better long-term company performance. However, it also represents a dilution of existing shares upon vesting and exercise.

Next Steps

• Pamela Ann Connealy must continue her service with Orchestra BioMed Holdings through June 23, 2027, for the RSUs and stock options to vest.
• The stock options can be exercised by their expiration date of June 23, 2036.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Securities Exchange Act